RxDoctor Payments Data

Erin McCormick-Kelly, NP

Adult Health · Mount Laurel, NJNPI 1033860903

Payments from drug & device makers

$2,633in general payments, 2019–2025

Across 138 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$761
  • Takeda Pharmaceuticals U.S.A., Inc.$345
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$268
  • Ardelyx, Inc.$250
  • Bristol Myers Squibb$208
  • Regeneron Healthcare Solutions, Inc.$173
  • plus $628 from 9 others

What the payments were for

  • Food & beverage$2,633100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,633 in reported general payments places this provider in the 85th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$9,596
Medicare patients
86
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase29$62,928
LinzessLinaclotide51$40,368
Dexlansoprazole DrDexlansoprazole12$6,532
Famotidine228$3,573
Omeprazole216$2,609
Pantoprazole Sodium121$1,349
Lubiprostone14$1,239
Dicyclomine Hcl57$1,237
Nizatidine11$1,102
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg44$976
Sucralfate18$968
Esomeprazole Magnesium29$766
Lansoprazole18$519
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl34$502
Ondansetron OdtOndansetron28$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$761$103,29780 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Mount Laurel

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →